Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Asset Writedowns and Impairment (2012 - 2025)

Bio-Techne's quarterly Asset Writedowns and Impairment came in at $84.2 million in Q2 2025, up 428.46% year-on-year from $15.9 million in Q2 2024, and up 2402.54% quarter-over-quarter from -$3.7 million in Q1 2025.

Bio-Techne has reported Asset Writedowns and Impairment for 5 years, with the latest figure at $84.2 million in Q2 2025.

  • For the quarter ending Q2 2025, Asset Writedowns and Impairment rose 428.46% year-over-year to $84.2 million; the trailing twelve-month figure through Jun 2025 stood at $96.4 million (up 505.51% YoY), and the FY2025 full-year result was $80.5 million, up 266.54% from the prior year.
  • Asset Writedowns and Impairment for Q2 2025 stood at $84.2 million, up from -$3.7 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $84.2 million in Q2 2025, with the low at -$3.7 million in Q1 2025.
  • Average Asset Writedowns and Impairment over 3 years is $23.1 million, with a median of $15.9 million recorded in 2024.
  • Peak annual rise in Asset Writedowns and Impairment reached 428.46% in 2025, while the deepest fall reached 428.46% in 2025.
  • Tracing TECH's Asset Writedowns and Impairment over 3 years: stood at $18.7 million in 2021, then slipped by 14.91% to $15.9 million in 2024, then jumped by 428.46% to $84.2 million in 2025.
  • The last three Asset Writedowns and Impairment figures came in at $84.2 million (Q2 2025), -$3.7 million (Q1 2025), and $15.9 million (Q2 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Bio-Techne 7.92 Bn 7.71 Bn 208.29 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 84.16 Mn
Jun 30, 2025 84.16 Mn
Mar 31, 2025 -3.66 Mn
Mar 31, 2025 -3.66 Mn
Jun 30, 2024 15.93 Mn
Jun 30, 2024 15.93 Mn
Dec 31, 2021 18.72 Mn
Dec 31, 2021 18.72 Mn
Sep 30, 2021 546,000.00
Sep 30, 2021 546,000.00
Mar 31, 2018 16.25 Mn
Mar 31, 2018 16.25 Mn
Mar 31, 2012 3.25 Mn
Mar 31, 2012 3.25 Mn